Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus ...
Arvinas (ARVN) stock faces a downgrade after underwhelming trial data for breast cancer drug vepdegestrant developed with ...
Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...
Investor's Business Daily on MSN6d
Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer DrugArvinas stock lost half its value Tuesday after the biotech company reported mixed results from its Pfizer-partnered breast ...
Arvinas & Pfizer announce positive topline results from phase 3 VERITAC-2 clinical trial: New Haven, Connecticut Wednesday, March 12, 2025, 10:00 Hrs [IST] Arvinas, Inc., a clinic ...
VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...
Wedbush became the latest brokerage to downgrade Arvinas (NASDAQ ... an experimental breast cancer therapy it co-develops with Pfizer (NYSE:PFE). On Tuesday, based on data from those with estrogen ...
and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial ...
Shares in US biotech Arvinas were more than 50% lower, and those in pharma giant Pfizer down 2%, at the mid-point of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback